$LBRX SEC Filings

Filed On	Filing
13 Oct 2026	Form 4: Kozauer Susan Gani, Chief Medical Officer Granted 200,000 Emplopyee Stock Option (Right to Buy)
13 Oct 2026	Form 4: Miller Joseph M, Chief Financial Officer Granted 200,000 Emplopyee Stock Option (Right to Buy)
13 Oct 2026	SCHEDULE 13G/A
05 Oct 2026	EFFECT
01 Oct 2026	POS AM
01 Oct 2026	S-3ASR
24 Sep 2026	Form 3: Kozauer Susan Gani, Chief Medical Officer No securities owned
15 Sep 2026	424B3
15 Sep 2026	8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Regulation FD Disclosure NEW YORK, September 15, 2026 (GLOBE NEWSWIRE) — LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the mu...
14 Sep 2026	Form 3: Miller Joseph M, Chief Financial Officer No securities owned
03 Sep 2026	424B3
03 Sep 2026	8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
14 Aug 2026	SCHEDULE 13G/A
11 Aug 2026	424B3
11 Aug 2026	10-Q
11 Aug 2026	8-K: Results of Operations and Financial Condition
03 Aug 2026	Form 4: Deep Track Biotechnology Master Fund, Ltd., 10% owner and 2 others Acquired 286,205 Pre-Funded Warrants (Right to Buy) (Open Market Purchase) ($10M)
29 Jul 2026	SCHEDULE 13G/A
29 Jul 2026	424B3
29 Jul 2026	8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

Comments